Acceleration of laboratory-based technical and computational cross-fertilization, and ethical and cost pressures on regulatory bodies and therapeutic innovators is driving advancements in preclinical human-based technologies.
Organ (Lab)-on-chip (OoC/LoC) is one of the most striking examples of new translational research technology expansion with ~35% CAGR expected over the next decade (below).
Collaborations between academia and CRO’s are driving improvements in organoid technology for the field of oncology broadly and are expected to improve OoC adoption. Academic innovation using commercial OoC technology is also advancing applications in specific indications in oncology. CRO’s continue to build off established uses in ADME and toxicology to explore R&D applications in oncology space and have even combined organ systems to support elaboration of multiple drug parameters in a single assay.
DEALS
The Tara Biosystems – Valo Health deal is a nice example of how an organ-on-a-chip technology approach has driven collaborations, acquisitions and deals:
- Tara Biosystems and GSK collaborate on CV drug profiling (2019)
- Valo Health acquires Tara Biosystems for CV OoC platform (2022, ~$75M upfront)
- Valo and Novo Nordisk sign CV drug discovery deal (2023, $60M upfront, $2.7B total)
Emulate, TissUse and Mimetas have also been backed by strong big pharma collaborations (AstraZeneca, Bayer, Roche) and funding rounds.
Next Phase Newsletter 
Leave a comment